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Abstract
Using hepatotoxic drugs in induction phase for ALL patients increases liver enzymes and deal to some difficulties. So, treatment with herbal medicine such as 
Silymarin in monitoring serum levels of liver enzymes in ALL patients is effective. In a clinical trial study, we selected randomly 30 all patients and divided in two 
groups. One group treated with Silymarin and another group takes placebo for 56 days. Laboratory tests were done in patients on days 0, 28 and 56. The mean serum 
ALT and AST levels in two groups were similar in days 0 and 28, but in day 56 a significant decrease was seen in Silymarin group compared to placebo. Results showed 
that, the use of Silymarin in induction phase of ALL treatment significantly reduces liver enzymes and side effects of chemotherapy and be effective in prevention of 
hepatotoxicity in ALL patients.
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Introduction
Acute Lymphoblastic Leukemia (ALL) is the most common cancer 
among children, one fourth of all cancers in children and 72% of all 
cancers in leukemia. The etiology of leukemia in children is unknown 
and probably multifactorial which genetic and environmental factors 
may involve in its occurrence. By recently research about treatment 
of childhood acute leukemia, the remission ratio of ALL patients has 
reached in 1950 from zero to 75-85%.The main treatment of ALL is 
chemotherapy. Increasing medical knowledge about chemotherapy 
drugs combination, known effective dose and the use of short-term or 
long-term disability supportive treatment have reduced the number of 
these patients. In some patients undergoing chemotherapy, the occurred 
side effects lead to dose reduction and delay in treatment process and 
increase the risk of a relapse. The side effects can be included liver 
toxicity caused by L. asparaginase and doxorubicin in induction stage, 
that any protocol has not been presented on controlling liver enzymes 
and reducing liver toxicity in the induction stage of the the patients. 
Recently, the effect of Silymarin in liver enzyme controlling of these 
patients has been taken into consideration but there is no extensive 
information about the effect of treatment and prophylaxis of the drug. 
Silymarin is a herbal medicine and, also, has been approved in the 
protection of liver in liver disease such as acute and chronic hepatitis 
and liver cirrhosis. This is an anti-cancer medication and exacerbate the 
effects of vincristine. Silymarins leads to liver protection by protecting 
against free radicals, increasing antioxidants and endogenous enzymes, 
liver cells’ membrane protection by reducing lipid peroxidation, 
stimulating protein synthesis, increasing the excretion of toxins and 
helping to liver regeneration [1-6]. The greatest impact of Silymarin 
is on reducing liver enzymes one month after starting medication, the 
use of Silymarin during the one month period of induction, in addition 
to the prevention of increase in liver enzymes in this period, reduces 
the hepatotoxic effects of drugs such as L. asparaginase, doxorubicin 
and 6-mercaptopurine [2-4] in the later stages of treatment and, 
consequently, facilitates the treatment. In Children Oncology, extensive 
studies on the effects of Silymarin in the prevention and treatment of 
hepatic and cardiac toxicity of chemotherapy drugs are being conducted 
[7]. The incidence rate of childhood cancer in Iran was 48 to 112 and 51 
to 144 per million among girls and boys in multi geographical settings, 
respectively. The most common cancer in children from 0 to 14 years 
old were leukemia (incidence rate=8 to 62/million), lymphoma, and 
central nervous system tumors. Tabriz is a big province in North West 
of Iran with population about 1,549,453 and more prevalent area for 
cancers [8].
According to Fathi et al., study, leukemia with 45 (54.2%), 
CNS with 12% and Lymphomas with 8.4% were the most prevalent 
malignancies in Ardabil province and form leukemia cases 86.7% were 
acute lymphatic leukemia (ALL). The cumulative incidence rate was 
95.4 patients per one million. More incidence rate was in year 2011 
with 92.8 per 1000000. The cumulative incidence rate in all children; 
girls and boys were 95.4, 85.9 and 10.3 per 1000000 of population. ALL 
with 47% were the prevalent cancer pathology in all age groups and 
also, most of ALL cases were in age groups 1-4 with 41% [9].
The aim of this study was to investigate the impact of Silymarin 
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on the prevention of liver toxicity (hepatotoxicity) in ALL patients 
undergoing induction treatment in Tabriz Province north west of Iran.
Methods and materials
In this single blind clinical trial study, 30 patients with inclusion 
criteria were randomly selected from all the patients diagnosed with 
ALL that were hospitalized at cancer and blood sector of Ebne Sina 
hospital in Tabriz city and were under the treatment of induction based 
on vincristine and L. asparaginase. No known liver or diabetic diseases 
were observed in the patients. The samples were divided randomly 
in two Silymarin group and placebo group each with 15 patients. 
Silymarin drug with 5 mg/kg/day dose in the first day of chemotherapy 
and placebo with the same dose for 28 days were given to each group. 
For all patients CBC-diff, ALT AST, Bili (Total, Direct), FBS tests were 
checked on 0th, 28th and 56th days. Na and K levels in Serum were 
checked on 0th, 15th and 28th days. In the 7th and 28th days and after 
the beginning of induction, aspiration of bone marrow was performed 
and the rate of improvement was assessed. PT and PTT were measured 
on 4th and 22th days and blood pressure was measured on 0th and 
28th days. Cardiac echo of these patients was performed on 0th and 
28th days. Information included age, sex, type of acute lymphoblastic 
leukemia (1L, 2L, 3L), bone marrow aspiration results, results of tests 
such as CBC-diff, ALT, AST, Bili (Total, Direct) FBS, echocardiogram, 
blood pressure measurement, side effects of chemotherapy and 
Silymarin were collected in a checklist and then analyzed. Drug 
side effects were fully explained to the patients before the study and 
consent form completed for all patients before admission to the study. 
This study was approval by the Ethics Committee of Ardabil Medical 
University (ARUMS1032) and registered in Iranian clinical trial 
(IRCT201408071325N2).
Results
40% of the cases aged less than 3 years and 40% in the control 
group aged 3-6 years. The average age of the patients in the case group 
was 4.8 ± 2.4 and in the control group was 5.8 ± 3.3 years and the 
difference wasn’t statistically significant. In both groups, 12 patients 
(80%) have ALL Type L1 and 3 patients (20%) have ALL Type L2. Of 
all patients, 21 patients (70%) have chemotherapy side effects, of which 
8 cases (53.3%) were in the case group and 13 patients (86.8%) in the 
control group and the difference between two groups was statistically 
significant (p=0/046).The average serum levels of ALT, AST and FBS 
at 56th day was significantly different between two groups, but there 
was no significant difference between two groups in the mean serum 
level of PLT in 56th day. There weren’t significant differences between 
the two groups in the number of the ultrasonography performed at the 
beginning of the study and doing BMA in the 7th day. Hepatomegaly 
frequency in both study groups was 66.7%. Values of Hb, total and 
direct bilirubin was similar between both groups in all the times. In 
case group, decreasing in the amount of FBS was significant at the 
beginning of the study compared to the 56th day and in the control 
group, increasing in the amount of ALT at the beginning of the study 
compared to the 28th and 56th days were significant and other changes 
were not statistically significant (Figures 1-4).
Discussion
Of 30 patients with ALL and undergoing induction therapy, 15 
patients treated with silymarin and 15 patients with placebo. In this 
study, only 2 patients (13.3%) in the control group (13/33%) having 
delay in the stages of chemotherapy and reducing in the treatment dose 
which was no significant difference between two groups. It has been 
noted that in long-term and extensive studies, the difference might be 
significant because Silymarin, in addition to anti-inflammatory effects, 
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Figure 1. Trend of changes in FBS amounts in two groups by study time.
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Figure 2. Trend of changes in PLT amounts in two groups by study time.
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Figure 3. Trend of changes in AST amounts in two groups by study time.
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Figure 4. Trend of changes in ALT amounts in two groups by study time.
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has anti-carcinogenic and anti-metastasis effects too [10]. The mean 
difference of ALT and AST serum levels between two groups were not 
statistically significant on 0th and 28th days, but in 56th day there was 
significant. (P=0.005) Average serum levels of AST and ALT in the case 
group slightly increased at the end of induction compared to 0th day 
but after discontinuation of the drug during the next first month (56th 
day), the drug effects were observed and the mean serum levels became 
even lower than the first day that shows the fact that the greatest impact 
of the drug is in the during first month after treatment. Average serum 
level of ALT in the control group in three study times significantly 
have increased trend (p=0.007) but no significant increase in mean 
serum level of AST in this group which these results indicate a greater 
impact of Silymarin in reducing ALT compared to AST and Since ALT 
compared to AST is more specific liver enzyme, the above results could 
be expected. Average serum levels of Bili.Total, Bili.Direct, WBC, Hb 
and Plt between two groups was similar in all study times. Average 
serum levels of FBS between two groups on 0th and 28th days was 
similar, but on 56th day a significant difference was observed between 
two groups (p=0.03). Given that Silymarin is more effective on liver so 
no significant effect on WBC, Hb and Plt is expected. 21 patients (70%) 
were suffering from side effects of chemotherapy. Of these, 8 patients 
(53.3%) were from the case group and 13 patients (86.7%) from the 
control group and difference between two groups was significant 
(p=0.046). Side effects included nausea and vomiting, neuropathy, 
diabetes and pancreatitis that all of them in the control group were 
higher and pancreatitis was not observed in the case group. It should 
be noted that about the side effects of Silymarin, particularly its long-
term side effects, some studies have been conducted but further studies 
are recommended about it [11-14]. Hosseini et al. in a study showed 
that treatment with Silymarin in patients with type II diabetes have 
had significant effects on gylcemic parameters improvement of the 
patients which also in the present study the FBS values in Silymarin 
group were significantly decreased compared to the control group. 
McBride and et al in a study showed that Silymarin have been useful 
in the management and prevention hepatotoxicity in patients treated 
for AML which is similar to the results of this study [3]. Ebrahimpur et 
al., showed in a study that Silymarin improves the antioxidant indexes 
in type II diabetic patients and Silymarin had a significant effect on 
reducing liver enzymes which the results is similar to our study results [15].
Conclusion
Results showed that the use of Silymarin in the induction phase 
of ALL treatment can significantly reduce the liver enzymes and then 
the side effects of chemotherapy. Also using this herbal medicine can 
be effective in the prevention of hepatotoxicity in ALL patients and 
for more results, doing future studies about use of Silymarin in other 
stages of chemotherapy with more samples is suggested.
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